阿斯利康第二季度销售额超预期，得益于强劲的抗癌药物收入，重申2025年展望-动脉网

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

benzinga 等信源发布 2025-07-29 09:48



可切换为仅中文







AstraZeneca Plc

阿斯利康公司

AZN

阿塞拜疆新马纳特

on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the

周二报道了2025年第二季度销售额为144.6亿美元，同比增长12%（按固定汇率计算增长11%），略高于预期。

consensus of $14.07 billion

共识为140.7亿美元

, driven by double-digit growth in oncology and biopharmaceuticals.

，受到肿瘤学和生物制药领域两位数增长的推动。

The company's adjusted EPADS reached $1.08, missing the consensus of $1.10. The adjusted EPS was $2.17 (1 ADR = 2 Common Shares).

公司调整后的每股收益（EPADS）达到1.08美元，低于市场普遍预期的1.10美元。调整后的每股收益为2.17美元（1份存托凭证ADR = 2股普通股）。

Also Read:

另请阅读：

Trump Tariffs Force AstraZeneca To Bring Substantial Pharmaceutical Production To US

特朗普关税迫使阿斯利康将大量药品生产带到美国

AstraZeneca's top business, oncology (cancer), accounted for 44% of total sales. It

阿斯利康的核心业务肿瘤学（癌症）占总销售额的44%。

increased

增加

18% (up 18% on constant currency) to $6.31 billion.

18%（按固定货币计算增长18%）至63.1亿美元。

Tagrisso sales were up 13% to $1.81 billion (12% at CER), Imfinzi revenues were up 27% (+26%) to $1.46 billion, Calquence sales increased 10% to $872 million, Lynparza sales increased 13% (+11%) to $838 million, and Enhertu revenue was up 41% (42% at CER) to $666 million.

Tagrisso的销售额增长了13%，达到18.1亿美元（按固定汇率计算增长12%），Imfinzi的收入增长了27%（+26%），达到14.6亿美元，Calquence的销售额增长了10%，达到8.72亿美元，Lynparza的销售额增长了13%（+11%），达到8.38亿美元，Enhertu的收入增长了41%（按固定汇率计算增长42%），达到6.66亿美元。

On Monday, the Food and Drug Administration (FDA)

周一，美国食品和药物管理局 (FDA)

accepted

接受

and granted Priority Review in the U.S. for AstraZeneca's supplemental Biologics License Application for Imfinzi (durvalumab) for resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.

美国已授予阿斯利康公司关于Imfinzi（durvalumab）的补充生物制品许可申请优先审查资格，用于可切除、早期和局部晚期胃癌及胃食管交界处癌症。

The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the fourth quarter of 2025.

《处方药使用者付费法案》的日期，即 FDA 做出监管决定的行动日期，预计将在 2025 年第四季度。

Cardiovascular, renal, and metabolism (CVRM) sales accounted for 23%, which increased by 3% (up 3% at CER) to $3.64 billion.

心血管、肾脏和代谢（CVRM）销售额占比23%，增长了3%（按固定汇率计算增长3%），达到36.4亿美元。

The largest selling drug in the segment, Farxiga, accounted for 15% of sales.

该领域销量最大的药物 Farxiga 占销售额的 15%。

It was up 11% (10% at CER) to $2.15 billion.

它上涨了11%（按固定汇率计算为10%），达到21.5亿美元。

Respiratory & Immunology (R&I) sales increased 13% (12% CER) to $2.15 billion.

呼吸系统和免疫学（R&I）销售额增长了13%（固定汇率CER为12%），达到21.5亿美元。

Symbicort revenues fell 1% (-1% CER) to $715 million, and Fasenra sales increased 19% (+18%) to $502 million.

Symbicort收入下降1%（-1% CER）至7.15亿美元，而Fasenra销售额增长19%（+18%）至5.02亿美元。

Rare Disease drug sales increased by 7% to $2.94 billion.

罕见病药物销售额增长了7%，达到29.4亿美元。

Trending Investment Opportunities

投资机会趋势

Arrived

到达

Buy shares of homes and vacation rentals for as little as $100.

只需 100 美元，即可购买房屋和度假租赁的股份。

Get Started

开始使用

WiserAdvisor

智慧顾问

Get matched with a trusted, local financial advisor for free.

免费匹配值得信赖的本地财务顾问。

Get Started

开始使用

Point.com

点点网

Tap into your home's equity to consolidate debt or fund a renovation.

利用您房屋的净值来合并债务或为装修提供资金。

Get Started

开始使用

Robinhood

罗宾汉

Move your 401k to Robinhood and get a 3% match on deposits.

将您的401k转移到Robinhood，并获得存款3%的匹配。

Get Started

开始使用

Ultomiris sales were up 25% (23% at CER) to $1.18 billion, offset by a 24% decline in Soliris (-22% at CER) to $530 million.

Ultomiris的销售额增长了25%（按固定汇率计为23%），达到11.8亿美元，而Soliris的销售额下降了24%（按固定汇率计为-22%），至5.3亿美元。

China's sales accounted for 12% of quarterly sales, up 5% on a reported basis to $1.71 billion (+5% at CER).

中国的销售额占季度销售额的12%，按报告基准增长5%至17.1亿美元（按固定汇率计算增长5%）。

Pascal Soriot

帕斯卡尔·索里奥特

, CEO of AstraZeneca,

阿斯利康首席执行官，

commented

已评论

on Tuesday, 'Our strong momentum in revenue growth continued through the first half of the year, and the delivery from our broad and diverse pipeline has been excellent, with 12 positive key Phase III trial readouts, including for

周二，「我们强劲的收入增长势头延续至今年上半年，我们广泛而多样化的研发管道交付成果优异，其中有 12 项关键的第三阶段试验结果积极，包括

baxdrostat,

巴克斯特罗stat，

gefurulimab

格菲鲁利单抗

, and

，以及

Tagrisso

泰瑞沙

, in just the past few weeks.”

“仅仅在过去的几周里。”

Guidance: